Drug
Intervention/Treatment
Intervention/Treatment is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph not_applicable
4
80%
Ph phase_4
1
20%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
4(80.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Other(3)
Detailed Status
unknown3
Completed2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 41 (20.0%)
N/A4 (80.0%)
Trials by Status
completed240%
unknown360%
Recent Activity
0 active trials
Showing 5 of 5
unknownnot_applicable
EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis
NCT06169696
unknownphase_4
Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome
NCT06131580
completednot_applicable
Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)
NCT00311168
completednot_applicable
The Effects of e+Shots Energy Beverage on Mental Energy
NCT03850275
unknownnot_applicable
Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study
NCT03594682
Clinical Trials (5)
Showing 5 of 5 trials
NCT06169696Not Applicable
EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis
NCT06131580Phase 4
Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome
NCT00311168Not Applicable
Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)
NCT03850275Not Applicable
The Effects of e+Shots Energy Beverage on Mental Energy
NCT03594682Not Applicable
Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5